{
    "clinical_study": {
        "@rank": "124458", 
        "acronym": "PanaMa", 
        "arm_group": [
            {
                "arm_group_label": "Maintenance Chemotherapy + Panitumumab", 
                "arm_group_type": "Experimental", 
                "description": "Maintenance therapy:\nPanitumumab 6 mg/kg prior to administration of chemotherapy Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15\nRe-induction upon progression:\nPanitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.\nmFOLFOX6: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
            }, 
            {
                "arm_group_label": "Maintenance Chemotherapy w/o Panitumumab", 
                "arm_group_type": "Experimental", 
                "description": "Maintenance therapy:\nFolinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15\nRe-induction upon progression:\nPanitumumab 6 mg/kg prior to administration of mFOLFOX6 chemotherapy.\nmFOLFOX6 chemotherapy: Oxaliplatin 85 mg/m2 over 2 hours on day 1 Folinic acid 400 mg/m2 over 2 hours on day 1 5-FU 2400mg/m2 46h continuous infusion day 1 - day 2 Repeat on day 15"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase II, randomized, multi-center, open-label, parallel-group study to evaluate\n      the progression-free survival during maintenance therapy.\n\n      Eligible patients will be treated within a 12-week induction therapy. Those patients\n      achieving CR/PR or SD at 12 weeks and qualifying for maintenance treatment and re-induction\n      treatment with all potential drug components, will be randomized in a ratio of 1:1 to\n      receive chemotherapy plus panitumumab or chemotherapy alone during maintenance. In case of\n      progression, re-induction treatment will be started."
        }, 
        "brief_title": "Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent\n\n          -  Male or female \u2265 18 years of age\n\n          -  Histologically proven metastatic colorectal cancer\n\n          -  Molecular testing showing RAS wild-type in colorectal carcinoma cells\n\n          -  Life expectancy > 12 weeks\n\n          -  At least one measurable lesion according to RECIST 1.1\n\n          -  Adequate bone marrow, liver, kidney, organ and metabolic function\n\n          -  Bone marrow function:\n\n               -  leukocyte count \u2265 3.0 \u00d7 109/L\n\n               -  ANC \u2265 1.5 \u00d7 109/L\n\n               -  platelet count \u2265 100 \u00d7 109/L\n\n               -  hemoglobin \u2265 9 g/dL or 5.59 mmol/L (may be transfused or treated with\n                  erythropoietin to maintain/ exceed this level)\n\n          -  Hepatic function:\n\n               -  Total bilirubin \u2264 1.5 \u00d7 UNL\n\n               -  ALT and AST \u2264 2.5 \u00d7 UNL (or \u2264 5 \u00d7 UNL in presence of liver metastases)\n\n               -  AP \u2264 5 \u00d7 UNL\n\n          -  Renal function:\n\n               -  Creatinine clearance \u2265 50 mL/min according to Cockcroft-Gault formula or serum\n                  creatinine \u2264 1.5 \u00d7 UNL\n\n          -  Metabolic function:\n\n               -  Magnesium \u2265 lower limit of normal\n\n               -  Calcium \u2265 lower limit of normal\n\n          -  ECOG performance status 0 - 1\n\n          -  Women of child-bearing potential must have a negative pregnancy test\n\n        Exclusion Criteria:\n\n          -  Previous treatment for colorectal cancer in the metastatic setting\n\n          -  Previous EGFR-targeting therapy < 6 months after end of adjuvant therapy\n\n          -  Known brain metastases unless adequately treated (surgery or radiotherapy) with no\n             evidence of progression and neurologically stable off anticonvulsants and steroids\n\n          -  Chronic inflammatory bowel disease\n\n          -  Peripheral neuropathy \u2265 NCI-CTCAE V 4.03 grade 2\n\n          -  Other previous malignancies with the exception of a history of previous curatively\n             treated basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix or\n             other curatively treated malignant disease without recurrence after at least 5 years\n             of follow-up\n\n          -  Significant disease that, in the investigator's opinion, would exclude the patient\n             from the study\n\n          -  History of cardiac disease; defined as:\n\n               -  Congestive heart failure > New York Heart Association (NYHA) class 2\n\n               -  Active coronary artery disease (myocardial infarction more than 6 months prior\n                  to start of study treatment is allowed)\n\n               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin\n                  are permitted)\n\n               -  Uncontrolled hypertension (defined as blood pressure \u2265 160 mmHg systolic and/or\n                  \u2265 90 mmHg diastolic on medication)\n\n          -  Patients with interstitial lung disease, e.g., pneumonitis or pulmonary fibrosis or\n             evidence of interstitial lung disease on baseline chest CT scan\n\n          -  Known HIV, hepatitis B or C infection\n\n          -  Known hypersensitivity reaction to any of the study components\n\n          -  Radiotherapy, major surgery or any investigational drug 30 days before registration\n\n          -  Pregnancy or lactation or planning to be pregnant during treatment and within 6\n             months after the end of treatment\n\n          -  Subject (male or female) is not willing to use highly effective methods of\n             contraception (per institutional standard) during treatment and for at least an\n             additional 6 months after the end of treatment\n\n          -  Known alcohol or drug abuse\n\n          -  Any condition that is unstable or could jeopardize the safety of the patient and his\n             compliance in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "280", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991873", 
            "org_study_id": "AIO-KRK-0212", 
            "secondary_id": "2012-005422-30"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Maintenance Chemotherapy + Panitumumab", 
                    "Maintenance Chemotherapy w/o Panitumumab"
                ], 
                "intervention_name": "Maintenance Chemotherapy", 
                "intervention_type": "Drug", 
                "other_name": "Folinic acid + 5-FU (5-Fluorouracil)"
            }, 
            {
                "arm_group_label": "Maintenance Chemotherapy + Panitumumab", 
                "intervention_name": "Panitumumab (Within maintenance phase)", 
                "intervention_type": "Drug", 
                "other_name": "Vectibix"
            }, 
            {
                "arm_group_label": [
                    "Maintenance Chemotherapy + Panitumumab", 
                    "Maintenance Chemotherapy w/o Panitumumab"
                ], 
                "intervention_name": "mFOLFOX6 (Within re-induction phase)", 
                "intervention_type": "Drug", 
                "other_name": "Oxaliplatin + Folinic acid + 5-FU (5-Fluorouracil)"
            }, 
            {
                "arm_group_label": [
                    "Maintenance Chemotherapy + Panitumumab", 
                    "Maintenance Chemotherapy w/o Panitumumab"
                ], 
                "intervention_name": "Panitumumab (Within re-induction phase)", 
                "intervention_type": "Drug", 
                "other_name": "Vectibix"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Oxaliplatin", 
                "Antibodies, Monoclonal", 
                "Leucovorin", 
                "Folic Acid", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "metastatic colorectal cancer", 
            "maintenance therapy", 
            "Panitumumab", 
            "Vectibix\u00ae"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": {
            "description": "Homepage of the AIO (Arbeitsgemeinschaft Internistische Onkologie in der Deutschen Krebsgesellschaft e.V.)", 
            "url": "http://www.aio-portal.de"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Schlegel, Dr. med.", 
                    "phone": "02403/76-1281"
                }, 
                "facility": {
                    "address": {
                        "city": "Eschweiler", 
                        "country": "Germany", 
                        "zip": "52249"
                    }, 
                    "name": "St.-Antonius-Hospital Eschweiler"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dr. Tanja Trarbach"
                }, 
                "facility": {
                    "address": {
                        "city": "Freiburg", 
                        "country": "Germany", 
                        "zip": "79106"
                    }, 
                    "name": "Praxis f\u00fcr interdisziplin\u00e4re Onkologie & H\u00e4matologie"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer", 
        "overall_contact": {
            "email": "d.bein@clinassess.de", 
            "last_name": "Daniela Bein, Dr."
        }, 
        "overall_contact_backup": {
            "email": "Helge.Schroeder@aio-studien-ggmbh.de", 
            "last_name": "Helge Schr\u00f6der, Dipl.Biol."
        }, 
        "overall_official": {
            "affiliation": "Praxis f\u00fcr interdisziplin\u00e4re Onkologie & H\u00e4matologie Freiburg", 
            "last_name": "Tanja Trarbach, Dr. med.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Ethics Commission", 
                "Germany: Paul-Ehrlich-Institut"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival during maintenance therapy defined as time from randomization until disease progression or death, whatever occurs first.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "Until end of follow-up (24 months after randomization)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991873"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from randomization until failure (death/ progression) of treatment strategy", 
                "measure": "failure of treatment strategy", 
                "safety_issue": "No", 
                "time_frame": "Until end of follow up (24 months after randomization)"
            }, 
            {
                "description": "Progression-free survival during re-induction therapy", 
                "measure": "Progression-free survival of re-induction", 
                "safety_issue": "No", 
                "time_frame": "From start of re-induction therapy until progress or end of follow-up (24 months after randomization)"
            }, 
            {
                "description": "Objective response after 12 weeks of induction chemotherapy", 
                "measure": "Objective response after 12 weeks of induction chemotherapy", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after start of induction chemotherapy"
            }, 
            {
                "description": "Objective best response during maintenance and re-induction", 
                "measure": "Objective best response during maintenance and re-induction", 
                "safety_issue": "No", 
                "time_frame": "Start of maintenance- until end of re-inductin therapy (expected average of 8 months)"
            }, 
            {
                "description": "Overall survival measured from time of randomization", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Until end of follow-up (24 months after randomization)"
            }, 
            {
                "description": "Overall safety", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Until end of follow-up (24 months after randomization)"
            }, 
            {
                "description": "Health and skin related Quality of life", 
                "measure": "Health and skin related Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Until end of follow-up (24 months after randomization)"
            }
        ], 
        "source": "AIO-Studien-gGmbH", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "ClinAssess GmbH", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Amgen", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "AIO-Studien-gGmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}